Candida tropicalis as a Predominant Isolate from Clinical Specimens and its Antifungal Susceptibility Pattern in a Tertiary Care Hospital in Southern India
Binesh Lal Yesudhason1, Kalyani Mohanram2
1 Associate Professor, Department of Clinical Microbiology, Christian Medical College, Vellore, India.
2 Professor, Department of Microbiology, Matha Medical College, Thandalam, Chennai, India.
NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR: Dr. Binesh Lal Yesudhason, Associate Professor, Department of Clinical Microbiology, Christian Medical College, Vellore -632004, India. E-mail : drbineshlaly@yahoo.com
Background
The incidence of infections caused by Candida species has increased considerably over the past three decades mainly due to the rise of the AIDS epidemic, an increasingly aged population, higher numbers of immunocompromised patients and the more widespread use of indwelling medical devices. Candida tropicalis is emerging pathogenic yeast among non-albicans species. Recently drug-resistant C.tropicalis was also reported in hospitals.
Aim and Objective
The present study aimed to isolate and speciate C. tropicalis from various clinical samples and to determine its antifungal susceptibility profile.
Materials and Methods
Clinical samples such as urine, blood, exudates and vaginal swab which were submitted to the Microbiology laboratory during the year 2013 were screened for the growth of Candidia species, which then identified as C.tropicalis by the routine microbiological procedures such as germ tube formation, assimilation and fermentation of sugars and colony color on HICHROM Candida agar. Antifungal susceptibility was performed by disc diffusion method with the drugs Amphotericin-B, Itraconazole, Ketaconazole and Fluconazole on C. tropicalis isolates.
Results
A total number of 112 Candida isolates were isolated during the year 2012 from various clinical specimens. Among them 61 (54.3%) were identified as C.tropicalis. All the C. tropicalis isolates were sensitive to Amphotericin-B (100%) but 23 isolates (37.7%) were resistant to Fluconazole.
Conclusion
We conclude that identification of Candida species is important to know the prevalent species in the clinical setup and routine antifungal susceptibility should be performed to avoid inappropriate treatment.
Introduction
In last three decades there has been a significant increase in the incidence of fungal infections in humans [1] ranging from superficial infections involving skin, hair and nail to systemic infections affecting major organs [2]. Various factors like widespread use of immunosuppressive drugs, use of broad-spectrum antibiotics, low-dose maintenance therapy and invasive surgical procedures are accounted for the increase incidence of fungal diseases [3,4]. Among the fungal infection in human beings, Candidial infections are predominantly reported. More than 200 species of Candida have been described, but approximately 90% of human invasive fungal infections are caused by only five species: Candida albicans, Candida tropicalis, Candida parapsilosis, Candida glabrata and Candida krusei [5]. Although Candida albicans remains the most common Candida species encountered, the morbidity and mortality caused bynon-albicans Candida (NAC) species are increasing [6].
C. tropicalis is now considered an important emerging fungal pathogen as it is associated with high mortality rate [7]. It is one of the most common Candida species that causes disease in humans, especially in tropical climates and it is responsible for 3 to 66% of cases of candidemia, depending on the geographic region [8].
C.tropicalis bloodstream infection accounts for 40 to 70% mortality [9], and these rates may vary depending on various other co-morbid conditions like leukemia, neutropenia and factors like central venous catheters and parental nutrition. In India, C.tropicalis is the most common cause of nosocomial Candidaemia. Epidemiological data from the Indian subcontinent showed that 67–90% of nosocomial Candidaemia cases were due to NAC species of which C.tropicalis was the most dominant [10].
Superficial mucosal C.tropicalis infections include oral thrush and vulvovaginitis. Meningeal, articular, osteomyelitis, pneumonia, endocarditis and pericardial infections has been reported. Urinary tract infections with C.tropicalis occur in patients with indwelling catheters, structural genitourinary abnormalities, diabetes mellitus and antibiotic therapy. C. tropicalis suppurative thrombophlebitis is related to intravenous therapy [11]. The increased isolation of this species from various Candida infections and emergence of azole resistance [12] necessitated the study. So, this study aims at determining the prevalence and antifungal susceptibility pattern of C. tropicalis from various clinical specimens in our clinical setup or hospital.
Materials and Methods
This study was done during a period of one year, from January 2013 to December 2013 in a teaching hospital, which is located at Chennai.The study was conducted after obtaining the ethical committee’s clearance and the university scientific review board’s approval. Samples such as urine, exudates, blood and vaginal swab were collected under aseptic techniques in a sterile container and transported immediately to laboratory. Urine samples were collected after giving proper instructions to patients and catheterized urine samples were collected using sterile syringe from the port of urine catheter.
The samples such as urine,exudates and vaginal swab were subjected to wet mount and Gram stain and inoculated on Sabouraud’s Dextrose Agar with Actidione slope. Blood samples were first inoculated in Brain heart infusion broth then after 48 hours it was subcultured on Sabouraud’s Dextrose Agar with Actidione slope. The inoculated media were incubated at 37°C for 24-48 hours. The isolates were considered significant by correlation with Gram stain, growth of two consecutive cultures and the clinical presentation. The suspected Candida colonies were processed further for their species level identification.
Identification of Candida species: The isolates had been identified by gram stain were further speciated by a panel of tests like germ tube test, morphology on corn meal agar, carbohydrate fermentation and assimilation tests [13].
Carbohydrate assimilation tests: The Candida species to be tested was freshly grown on a carbohydrate free medium like nutrient agar. A suspension of the isolate in saline or distilled water was prepared.The surface of the agar plate was inoculated by rotating a swab soaked in suspension and the agar surface was allowed to dry. With a sterile forceps carbohydrate discs (filter paper discs impregnated with a drop of test sugar) were placed on the surface of the medium. The sugars used in this test were Glucose, Sucrose, Lactose, Maltose, Galactose, Cellibiose and Trehalose. The plate was incubated at 30°C for 24-48 hours. After incubation, the plate was removed and observed. A positive result is indicated by the presence of growth surrounding the carbohydrate discs. The carbohydrates assimilated by the Candida species were noted and the species identification was done by comparing with the standard chart [14].
Carbohydrate fermentation tests: Overnight incubated isolates in nutrient agar was inoculated in the individual sugar tubes and incubated at 37°C for 10 days. The sugars used for the study were Dextrose, Lactose, Sucrose, Galactose, Trehalose and Maltose. Individual sugars are prepared with Yeast extract, peptone and Bromothymol blue as indicator. Acid or acid and gas production was noted in each tube and accordingly speciation was done [15]. C.tropicalis ferments with gas production in dextrose, sucrose, maltose, galactose, and trehalose but does not ferment lactose.
HiCrome Candida differential agar M1456A was obtained commercially from Hi Media, Mumbai, India. As this agar is intended to differentiate the Candida spp by producing different pigment and colony morphology it is used in our study [16]. It identifies steel blue to blue as C. tropicalis, light green colonies as C. albicans, cream to white as C. glabarata and purple fuzzy colonies as C. krusei. The medium was prepared as per the instructions given by the manufacturer and the colonies from SDA were subcultured on it and observed for the colony appearance and pigment production.
Antifungal susceptibility testing was performed by disc diffusion method on Yeast Nitrogen Base Glucose Agar (YNBGA). A lawn culture was made with the medium and commercially available antifungal disks (Himedia) Amphotericin B, Ketaconazole, Itraconazole, and Fluconazole (10μl) were placed and incubated at 35°C for 48 hours [17].
Results
A total number of 238 Candida isolates were isolated during the year 2013 (Jan to Dec). Among them 112 non-repeat isolates of Candida were included in the study after confirming the growth in the second sample. A total of 61 C.tropicalis was isolated from various clinical specimens. [Table/Fig-1] show the clinical specimen wise distribution of C. tropicalis. Majority of the isolates were obtained from urine samples 39 (63.93%) followed by vaginal swabs 12 (19.67%). Among the 61 isolates 43 (70.5%) were from critically ill patients admitted in ICU and 18(29.5%) from non-ICU patients. Out of 39 C. tropicalis isolated from urine samples; 35 isolates were from catheterized patients and 4 from non-catheterized patients. Other isolates apart from C.tropicalis were speciated and the results as follows: C.albicans 42 (37.5%). C. parapsilosis 6 (5.4%) and the least common isolate was C.glabrata 3 (2.7%). All the C.tropicalis isolates formed blue colour colonies on CHROM agar medium.The antifungal susceptibility testing for C.tropicalis was performed by disc diffusion method with the drugs, Amphotericin-B, Itraconazole, Ketaconazole and Fluconazole. All the C. tropicalis isolates were sensitive to Amphotericin-B (100%) but 26 isolates (37.7%) were resistant to Fluconazole. [Table/Fig-2] show the antifungal susceptibility pattern of C.tropicalis.
Distribution of C tropicalis in various specimens
| Samples | Urine | Vaginal Swab | Exudates | Blood | Total |
|---|
| No of C.tropicalis isolates | 39(63.93%) | 12(19.67%) | 04(6.55%) | 06(9.83%) | 61 |
Sensitivity and resistance pattern of C.tropicalis for Antifungal drugs
| Number of C.tropicalis Isolates | Amphotericin-B | Itraconazole | Ketoconazole | Fluconazole |
|---|
| S | R | S | R | S | R | S | R |
|---|
| 61 | 61 (100%) | _ | 45 (73.8%) | 16 (26.2%) | 46 (75.4%) | 15 (24.6%) | 38 (62.3%) | 23 (37.7%) |
*The values represented were statistically significant (p<0.05) at 95% CI
Discussion
Candidiasis is defined as infections caused by Candida species. It is considered as commensals in healthy individual and its capacity to produce superficial or systemic infections depends on the host immune system and various risk factors [18].
In recent years there is remarkable increase in the opportunistic pathogen Candida which causes life threating infections in immunocompromised patients [19]. HIV infection, the new world pandemic provided a potent soil for Candidial infection. Modern medical procedures of various kinds contribute to the risk factors for developing Candidiasis. The early identification and antifungal susceptibility testing is necessary for decrease of mortality rate.
In the present study 112 non-repeat isolates of Candida were speciated. C.tropicalis was the predominant isolate from clinical samples 61 (54.5%); similar observation was also reported by other researchers or studies [20,21]. Out of 39 urine isolates 35 (89.7%) patients had urinary catheterization as a risk factor. Kobayashi CC et al., in their study observed that one of the principle risk factors in patients with candiduria was urinary catheterization (38.4%) [22]. Another multicentre surveillance study had documented the removal of catheter has cleared funguria in 31.3% of their patients. So, all these studies favour urinary catheterization as one of the risk factor in candiduria [23]. Our observation of higher percentage (70.5%) of C.tropicalis isolation in ICU could be due to previous history of treatment with broad spectrum antibiotics, or total parenteral nutrition or cytotoxic chemotherapy and other co-morbid conditions such as was diabetes mellitus and malignancy.
Next to urine, 19.67% of C.tropicalis was isolated from vaginal swab. Similar observation was made by another study where the isolation of C.tropicalis from vaginal swab was the second to urine specimen. Studies have identified pregnancy; uncontrolled diabetes and practise of low dosage azole in the treatment of various Candida infections were predisposing factors for C. Tropicalis vulvovaginitis [20].
We identified 6(9.83%) cases of C.tropicalis fungemia in ICU patients. C.tropicalisis responsible for 3 to 66% of cases of candidemia, depending on the geographic region and mortality rates of 40 to 70% have been associated with the presence of C. tropicalis in the bloodstream. ICU stay, total parenteral nutrition (TPN), prior exposure to fluconazole, and diabetes mellitus were the major risk factors for candidemia [7]. Pathogenesis of Candidiasis depends on expression of various virulence factors like adhesins, phenotypic switching, thigomotropism and hydrolytic enzymes [24]. Above all, expression of these virulence factors may vary depending on the infecting species, geographical origin, type of infection, the site and stage of infection, and host immune response [20].
Some studies showed that C. tropicalisis even more invasive than C. albicans in the human intestine, particularly in oncology patients and they express increased virulence factors in immunocompromised patients [25]. Various virulence factors [26] are responsible for forming biofilm by Candida spp. and detection of these virulence factors remains a key indicator of possible haematogenous infection.
C.tropicalis has its ability to express variety of virulence factors [20] indicating its capacity to contribute to the pathogenesis and produce invasive infections. Furthermore, C. tropicalis causes invasive disease in neonatal intensive care units (ICUs) through cross-contamination and has a slight tendency to progress from colonization to infection [6].
C.tropicalis is being increasingly isolated from human disease and is associated with invasive infection it remains a major concern because of its ability to develop rapid resistance to fluconazole. Resistance to antifungal agents has represented a major challenge for the clinic and a major public health problem. In our study, all the C. tropicalis isolates were sensitive to amphotericin-B (100%) but 23 isolates (37.7%) were resistant to fluconazole. When compared with itraconazole and ketaconazole, the fluconazole had shown higher degree of resistance. Similar observation was made by another study in India [27] where fluconazole resistance was high (38.8%) when compared to ketoconazole (28.2%) and itraconazole (32.9%). As determined by other study [28], we also observed maximum resistance to fluconazole. Resistance to azole by C. tropicalis is mediated by up-regulation and mutations of ERG11 gene [6]. The increasing rate of fluconazole resistance in C.tropicalis remains a major concern in the management of its infection. All the C.tropicalis isolates were sensitive to amphotericin; its use is limited in the treatment because of various side effects including renal toxicity [27].
Conclusion
C. tropicalis, cannot be overlooked as contaminants or non-pathogenic commensals. It remains an important pathogen, especially in ICU patients. Studies have shown increased prevalence and high incidence of drug resistance in C. tropicalis, as well as increased morbidity and mortality caused by this pathogen in hospitalized individuals, identification and susceptibility tests should be performed on all yeast isolates for appropriate therapy and it will potentially reduce the risk of drug-resistant life-threatening infections and nosocomial infections.
*The values represented were statistically significant (p<0.05) at 95% CI
[1]. Silva S, Negri M, Henriques M, Oliveira R, Williams DW, Azeredo J, Candida glabrata, Candida parapsilosis andCandida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance FEMS Microbiol Rev 2012 36:288-305. [Google Scholar]
[2]. Ruping MJ, Vehreschild JJ, Cornely OA, Patients at high risk of invasive fungal infections: when and how to treat Drugs 2008 68:1941-62. [Google Scholar]
[3]. Hagerty JA, Ortiz J, Reich D, Manzarbeitia C, Fungal infections in solid organ transplant patients Surg Infect 2003 4:263-71. [Google Scholar]
[4]. Kojic EM, Darouiche RO, Candida infections of medical devices Clin Microbiol Rev 2004 17:255-67. [Google Scholar]
[5]. Pfaller MA, Diekema DJ, Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida Clin Microbiol Infect 2004 10:11-23. [Google Scholar]
[6]. Jiang C, Dong D, Yu B, Cai G, Wang X, Ji Y, Mechanisms of azole resistance in 52 clinical isolates of Candida tropicalis in China Antimicrob Chemother 2013 68:778-85. [Google Scholar]
[7]. Chen YL, Yu SJ, Huang HY, Chang YL, Lehman VN, Silao FGS, Calcineurin Controls Hyphal Growth, Virulence, and Drug Tolerance of Candida tropicalis Eukaryotic Cell 2014 13(7):844-54. [Google Scholar]
[8]. Chai LY, Denning DW, Warn P, Candida tropicalis in human disease Crit Rev Microbiol 2010 36:282-98. [Google Scholar]
[9]. Leung AY, Chim CS, Ho PL, Cheng VC, Yuen KY, Lie AK, Candida tropicalis fungaemia in adult patients with haematological malignancies: clinical features and risk factors J Hosp Infect 2002 50:316-19. [Google Scholar]
[10]. Kothari A, Sagar V, Epidemiology of Candida bloodstream infections in a tertiary care institute in India Indian J Med Microbiol 2009 27:171-12. [Google Scholar]
[11]. Stratton CW, Stratton CW, Candida tropicalis Infection Control 1989 10(6):280-83. [Google Scholar]
[12]. Yang YL, Ho YA, Cheng HH, Ho M, Lo HJ, Susceptibilities of Candida species to amphotericin B and fluconazole: the emergence of fluconazole resistance in Candida tropicalis Infect Cont Hosp Ep 2004 25(1):60-64. [Google Scholar]
[13]. Pfaller MA, Houston A, Coffmann S, Application of CHROM agar Candida for rapid screening of clinical specimens for Candida albicans, Candida tropicalis, Candida kruseiandCandida (Torulopsis) glabrata J ClinMicrobiol 1996 34:58-61. [Google Scholar]
[14]. Warren NG, Hazen KC, Candida, Cryptococcus, and other yeasts of medical importance in Manual of clinical microbiology, eds Murray P. R., Baron E. J., Pfaller M. A., Tenover F. C., YolkenR. H. 1995 6th edWashington, D.CAmerican Society for Microbiology:723-37. [Google Scholar]
[15]. Cooper BH, Hutner MS, Yeasts of Medical importance Manual of clinical microbiology 1991 5th editionASM publications [Google Scholar]
[16]. Shettar SK, Patil AB, Nadagir SD, Shepur TA, Mythri BA, Gadadavar S, Evaluation of HiCrome differential agar for speciation of Candida J Acad Med Sci 2012 2(3):101-14. [Google Scholar]
[17]. Chander J, Candidiasis Text book of Medical Mycology 2009 3rd edMehta Publishers:266-90. [Google Scholar]
[18]. De Cássia Orlandi Sardi J, de Souza Pitangui N, Gullo FP, e Maria José Soares Mendes Giannini AMFA, A Mini Review of Candida Species in Hospital Infection: Epidemiology, Virulence Factor and Drugs Resistance and Prophylaxis Trop Med Surg 2013 1(5):141 [Google Scholar]
[19]. Neppelenbroek KH, Campanha NH, Spolidorio DMP, Spolidorio LC, Seó RS, Pavarina AC, Molecular fingerprinting methods for the discrimination between C. albicans and C. dubliniensis Oral Diseases 2006 12(3):242-53. [Google Scholar]
[20]. Deorukhkar SC, Saini S, Mathew S, Virulence Factors Contributing to Pathogenicity of Candida tropicalis and Its Antifungal Susceptibility Profile Int J Microbiol 2014 2014:1-6. [Google Scholar]
[21]. Shivaprakasha S, Radhakrishnan K, Karim P, Candida spp. other than Candida albicans: A major cause of fungaemia in a tertiary care centre Indian J Med Microbiol 2007 25:405-07. [Google Scholar]
[22]. Kobayashi CC, de Fernandes, Miranda KC, de Sousa ED, Silva Mdo R, Candiduria in hospital patients: a study prospective Mycopathologia 2004 158(1):49-52. [Google Scholar]
[23]. Kauffman CA, Vazquez JA, Sobel JD, McKinsey HG, Prospective Multicenter Surveillance Study of Funguria in Hospitalized Patients Clin Infect Dis 2000 30(1):14-18. [Google Scholar]
[24]. Sardi JCO, Scorzoni L, Bernardi T, Fusco-Almeida AM, Giannini MJS, Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options J Med Microbiol 2013 62(1):10-24. [Google Scholar]
[25]. Kothavade RJ, Kura MM, Valand AG, Panthaki MH, Candida tropicalis: its prevalence, pathogenicity and increasing resistance to fluconazole J Med Microbiol 2010 59:873-80. [Google Scholar]
[26]. Gokce G, Cerikcioglu N, Yagci A, Acid proteinase, phospholipase, and biofilm production of Candida species isolated from blood cultures Mycopathologia 2007 164:265-69. [Google Scholar]
[27]. Deorukhkar SC, Saini S, Non albicans Candida species: Its isolation pattern, species distribution, virulence factors and antifungal susceptibility profile Int J Med Sci Public Health 2013 2:533-38. [Google Scholar]
[28]. Myoken Y, Kyo T, Fujihara M, Sugata T, Mikami Y, Clinical significance of breakthrough fungemia caused by azole-resistant Candida tropicalis in patients with hematologic malignancies Haematol 2004 89:378-80. [Google Scholar]